- Home
- LPAA vs CAPR Comparison
LPAA vs CAPR Comparison
Compare LPAA & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPAA
- CAPR
- Stock Information
- Founded
- LPAA 2024
- CAPR 2005
- Country
- LPAA United States
- CAPR United States
- Employees
- LPAA N/A
- CAPR N/A
- Industry
- LPAA
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPAA
- CAPR Health Care
- Exchange
- LPAA Nasdaq
- CAPR Nasdaq
- Market Cap
- LPAA 299.3M
- CAPR 324.6M
- IPO Year
- LPAA 2024
- CAPR N/A
- Fundamental
- Price
- LPAA $10.52
- CAPR $6.18
- Analyst Decision
- LPAA
- CAPR Strong Buy
- Analyst Count
- LPAA 0
- CAPR 6
- Target Price
- LPAA N/A
- CAPR $23.00
- AVG Volume (30 Days)
- LPAA 13.3K
- CAPR 1.0M
- Earning Date
- LPAA 01-01-0001
- CAPR 11-12-2025
- Dividend Yield
- LPAA N/A
- CAPR N/A
- EPS Growth
- LPAA N/A
- CAPR N/A
- EPS
- LPAA 0.35
- CAPR N/A
- Revenue
- LPAA N/A
- CAPR $13,392,150.00
- Revenue This Year
- LPAA N/A
- CAPR N/A
- Revenue Next Year
- LPAA N/A
- CAPR $7,894.07
- P/E Ratio
- LPAA $29.87
- CAPR N/A
- Revenue Growth
- LPAA N/A
- CAPR N/A
- 52 Week Low
- LPAA $9.97
- CAPR $5.68
- 52 Week High
- LPAA $10.70
- CAPR $22.90
- Technical
- Relative Strength Index (RSI)
- LPAA 56.40
- CAPR 40.96
- Support Level
- LPAA $10.50
- CAPR $6.05
- Resistance Level
- LPAA $10.52
- CAPR $6.42
- Average True Range (ATR)
- LPAA 0.01
- CAPR 0.34
- MACD
- LPAA -0.00
- CAPR -0.07
- Stochastic Oscillator
- LPAA 50.00
- CAPR 8.95
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.